Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the &quot;New to CAM2029&quot; Patient Subgroup in a Phase 3 Study (ACROINNOVA 2)

Somatuline Depot (lanreotide prolonged-release subcutaneous) - Ipsen, Teijin

Oclaiz (octreotide subcutaneous depot) - Camurus

octreotide acetate - Generic mfg.

https://www.abstractsonline.com/pp8/#!/11016/presentation/8495

D. Ferone1; J. L. Spencer-Segal2; G. Fidan Yaylali3; M. Doknic4; E. Isaeva5; A. Dreval6; A. Gilis-Januszewska7; E. Gezer8; I. Bancos9; L. Katznelson10; M. Harrie11; A. Svedberg11; A. M. Pedroncelli11; F. Tiberg11

May 5, 2024